Inova Translational Medicine Institute Partners with Translational Software on MediMap™, an Optional Newborn Pharmacogenomic Test at Inova Women’s Hospital

BELLEVUE, Wash.–(BUSINESS WIRE)–Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support and precision medicine, today announced a 12-month pilot with Inova Translational Medicine Institute (ITMI), a research institute developing innovative methods for personalized healthcare. Use of TSI’s pharmacogenomics (PGx) knowledge base and PGx platform will enable Inova to integrate genomic information at the point of birth to personalize patient treatment and improve health outcomes.
Launched in February 2016, Inova now offers an optional one-time pharmacogenomic test called MediMap^™ for babies born at the new Inova Women’s Hospital, located on the Inova Fairfax Medical Campus. The optional MediMap test evaluates seven actionable genes associated with more than 21 drugs to determine how a baby will uniquely respond to certain prescription medications, including effectiveness and adverse reactions.
TSI’s proprietary knowledge platform is being used to classify and interpret raw genetic data from the MediMap test to generate a tailored, clinically meaningful report for each newborn with concise molecular intelligence and critical alerts regarding drug efficacy, toxicity, and known interactions to guide clinical decision making and enable physicians to prescribe the safest, most effective medications.
“Having an advance understanding of a newborn’s genetic makeup and response to commonly prescribed medications gives our physicians and community a tool to help personalize treatments for life,” stated Benjamin Solomon, MD, Chief, Division of Medical Genomics at ITMI. “We are excited to partner with Translational Software to help Inova stay at the cutting edge of molecular diagnostics and practice genomic medicine in real time. This partnership is a key milestone in Inova’s ongoing mission to be a global leader in personalized medicine by integrating genomic research into patient-centered care.”
Results and reports from the MediMap test are stored in Inova’s electronic health record system, as well as in Inova’s patient portal, called MyChart.
Don Rule, CEO of Translational Software, stated, “We are incredibly proud to be working with a visionary organization like ITMI to inform and assist their physicians and patients in the interpretation and use of PGx information. Pharmacogenomic testing at birth offers an immediate opportunity to put precision medicine into practice that grows in value throughout the patient’s lifetime to guide effective treatment.”
About Inova Translational Medicine Institute
The Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute delving into the genomics component of personalized medicine. ITMI utilizes genomic and clinical information from patients to develop innovative methods for personalized patient care. Pilot studies at the Institute have generated a large genomic and clinical data set that can be used as pilot data in a variety of fields, from computational biology to psychology as well as more obvious biomedical research applications. ITMI’s goal is to utilize information from its pilot studies to better understand and predict the onset of disease, leading to the implementation of preventive medicine based on the unique genomics of the individual patient.
About Translational Software, Inc.
Translational Software provides end-to-end solutions to support laboratories and healthcare providers adopting personalized medicine. Its powerful PGx portal transforms genomic and molecular data into actionable knowledge, integrating the best available clinical decision support with laboratory and clinical information systems to guide therapeutic options for medication management to enhance patient care. For more information visit www.translationalsoftware.com